This study is testing a new drug called EPI-7386 for men with a type of prostate cancer that keeps growing despite low testosterone, known as castration-resistant prostate cancer (CRPC). The study wants to learn if the drug is safe and find the right dose. Since this is the first time EPI-7386 is being tested in humans, researchers will also observe its effects on prostate cancer and how it interacts with other drugs.

• The study is in two parts. In Part A, researchers will test EPI-7386 alone. In Part B, they will add another treatment, Apalutamide, for some patients.
• To join, you must be a man 18 or older with specific prostate cancer history and have tried other treatments.
• There may be side effects, and the study requires multiple visits. Compensation details are not provided.

This study is important as it may lead to new treatments for prostate cancer, but there are risks since it's a new drug. Please consider your health history and consult with your doctor before participating.